As such, rescuing the Treg population may represent a potential therapeutic strategy in improving metabolic parameters during obesity; treatments with PPARγ agonists such as thiazolidinedione, 5-aminosalicylic acid (5ASA) or IL-33 administration in vivo were shown to regulate VAT Treg numbers and improve metabolic parameters in obese mouse models (160, 164, 165, 177). The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.